Navigation Links
Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
Date:6/2/2011

WALTHAM, Mass., June 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."   This follows the UK issuance which was granted in October of 2010 adding to the extensive patent estate.

The patent covers the novel polymorph form B of the oral histone deacetylase inhibitor, entinostat, being developed by Syndax for combination therapy with aromatase inhibitors for metastatic breast cancer and erlotinib for advanced non-small cell lung cancer.

"This U.S. allowance comes at a strategic time for Syndax and the development of entinostat since we now have the results of our randomized Phase 2 placebo-controlled study in metastatic breast cancer in hand and we are advancing entinostat in to Phase 3 studies," said Joanna Horobin, president and chief executive officer of Syndax. " We believe entinostat may help address the significant need to improve outcomes for the thousands of women in the United States living with metastatic breast cancer  by extending the benefit of hormone therapy and delaying initiation of chemotherapy. With patent life extending through 2029, we are looking forward to maximizing the opportunities to develop entinostat in multiple indications."  

About Entinostat

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat was tested in patients with advanced breast cancer in combination with aromatase inhibitors in  a randomized, placebo-controlled phase 2 trial.  The results will be presented at a scientific conference later this year and the Company is planning to move into pivotal trials at the
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... May 21, 2013  LCA-Vision Inc. (NASDAQ: LCAV ... the Lasik Plus ® brand, announces that all nominees to ... at today,s annual meeting of stockholders.  These Directors are: ... President of Bahl & Gaynor Investment Counsel , ... , Edgar F. Heizer III , ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
... VILLAGE, Colo. , June 28 Recondo ... the healthcare industry, announced today the general availability of ... and disparate hospital systems, applications, software services, and databases. ... developed decades ago, hospitals have been forced to deploy ...
... 28 Reportlinker.com announces that a new market research report is available in its ... Global Melanoma Therapeutics industry , ... http://www.reportlinker.com/p0197206/Global-Melanoma-Therapeutics-industry.html , ... analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive ...
Cached Medicine Technology:Recondo Technology Announces Integration Initiative for US Hospital Systems 2Recondo Technology Announces Integration Initiative for US Hospital Systems 3Recondo Technology Announces Integration Initiative for US Hospital Systems 4Global Melanoma Therapeutics Industry 2Global Melanoma Therapeutics Industry 3Global Melanoma Therapeutics Industry 4Global Melanoma Therapeutics Industry 5Global Melanoma Therapeutics Industry 6Global Melanoma Therapeutics Industry 7Global Melanoma Therapeutics Industry 8Global Melanoma Therapeutics Industry 9Global Melanoma Therapeutics Industry 10Global Melanoma Therapeutics Industry 11Global Melanoma Therapeutics Industry 12
(Date:5/22/2013)... 22, 2013 In partnership with ... Surge, LLC, E-Dentists.com has launched a new SEO ... feature numerous topics of interest to dentists and ... dental health. , http://www.E-Dentists.com/Blog/ , Blogging ... marketing. In addition to addressing keyword placement and ...
(Date:5/22/2013)... May 22, 2013 Teams who focus ... improvements use the new Do-Done StepTracker whiteboard as a ... the Do-Done board to display the current status of ... production cells and departments is listed down the side ... start a project, the squares are filled with yellow ...
(Date:5/22/2013)... MA New research from Brigham and Women,s Hospital ... fibrosis, an uncommon but deadly lung disease, may be ... These findings will be presented at the American ... the New England Journal of Medicine on ... 2013 print edition., "While this variant of the MUC5B ...
(Date:5/22/2013)... John Mathews from the University of Melbourne said this ... the undoubted benefits from CT scans in diagnosing and ... the British Medical Journal today and involved ... and the International Agency for Research on Cancer in ... were very useful in providing detailed three dimensional pictures ...
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
Breaking Medicine News(10 mins):Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:Registry questions superiority of bivalirudin over heparin 2
... study has found that Hypnotherapy can be used to relieve ... ,In a small study researchers randomly divided 28 patients ... group received 12 sessions of hypnotherapy over 17 weeks while ... placebo or dummy medicine. , ,According to the BMJ, ...
... Endocrinologists (AACE) Fifteenth Annual Meeting and Clinical Congress to ... 26-30 will discuss important benefits //of vitamin D and ... ,Vitamin D has been in the new ... has been attributed to it. Recent studies have highlighted ...
... According to a large study by Boston University, Black women ... greater risk of breast cancer.// ,The study was published ... Medicine., ,This study is unique because there are previous ... and so it would benefit. ,Lead researcher Dr. Lynn ...
... Madhya Pradesh fell ill after feasting at a marriage dinner, ... police said Thursday. // ,While 65 affected people ... after first aid, a hospital spokesman said. ,Earlier, ... feast. ,While many of those admitted to hospital ...
... have found a link between diet and ALS saying ... progression of Amyotrophic Lateral Sclerosis (ALS). // The Mount ... a correlation between diet and neuronal cell death, the ... an adult-onset neurodegenerative disorder in which spinal and cortical ...
... funded the sex-swap surgery of a former sailor is now ... Bainbridge, 57, from Middleton, says she needs the ?2,500 laser ... wear sleevless dresses in the summer. ,Middleton and ... is waiting for a date for surgery at Charing Cross ...
Cached Medicine News:
... plate system is a family of plates ... provides for consistent, reliable fixation of plate ... or backout. This innovative design eliminates the ... implant your screws and the swivel ring ...
... is a leading provider of telemedicine ... with state-of-the-art technology deliver accurate, reliable ... healthcare professionals and clients in improving ... and ECG technology to gather patient ...
... a high performance temperature controlled shaker which ... speed and incubation time are fully programmable ... are displayed on the LCD in real ... the microplates provide uniform incubation with less ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: